aCGT Vector DAC secured Irish Government Disruptive Technologies Innovation funding and as part of a public private partnership consortium that will invest €10.5m in bringing together a world class team of cellular therapy expertise.

A GMP Licensed ATMP (Advanced Therapy Medicinal Products) Point-of-Care Facility within a world renowned known world class GMP Licensed ATMP (Advanced Therapy Medicinal Products) Facility within Trinity College Dublin Modern Medicines Initiative.

This ‘beyond translational‘ scientific collaboration will be the start of an initiative that will bring standardised and localised delivery of safe and effective transformational and potentially curative Cellular therapies to many more patients globally, by strategically locating aCGT Vector’s ATMP GMP-in-a-BOX in Cellular Therapy hospital centres of excellence.

The overriding goal of aCGT Vector is make more Cellular Therapy Procedures more accessible to more Patients globally; by lowering the cost per treatment and reducing therapy failure rates from the current 45% at manufacture and 50% 3 years into treatment.

Why work with us

aCGT Vector operates within a specialised cancer centre of excellence with access to patients, consultants, within a growing Irish cellular therapy ecosystem, ripe for clinical trials to initiate at a lower cost base to be able to access the EU market, as a land bridge centre.